Showing results (1421-1430 of 1,771) with videos related to

Sort By:
Pageof 178
Neurourology and Urodynamics|June 13, 2017
Effects of pedunculopontine nucleus stimulation on human bladder functionHolly A Roy, Debbie Pond, Christopher Roy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 1990
IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cellsR W Kozak, H Lorberboum-Galski, L Jones, et al.
AIDS Research and Human Retroviruses|June 1, 1990
Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functionsE A Berger, V K Chaudhary, K A Clouse, et al.
Food Research International (Ottawa, Ont.)|March 28, 2018
Atlantic salmon (Salmo salar) co-product-derived protein hydrolysates: A source of antidiabetic peptidesPádraigín A Harnedy, Vadivel Parthsarathy, Chris M McLaughlin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 18, 2008
Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trialTakao Hasegawa, Junya Ako, Bon-Kwon Koo, et al.
Radiation Research|March 1, 1992
The v-src oncogene may not be responsible for the increased radioresistance of hematopoietic progenitor cells expressing v-srcM A Santucci, P Anklesaria, S M Anderson, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2010
Trauma history and risk of the irritable bowel syndrome in women veteransD L White, L S Savas, K Daci, et al.
Minerva Cardioangiologica|February 9, 2007
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II TrialJ Fajadet, W Wijns, G-J Laarman, et al.
Developmental Cell|December 5, 2006
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1David A Guertin, Deanna M Stevens, Carson C Thoreen, et al.
Leukemia & Lymphoma|May 24, 2011
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737David J Fitzgerald, Elizabeth Moskatel, Gal Ben-Josef, et al.
Pageof 178